JG was a 46-year-old man with acquired immune deficiency syndrome (AIDS) proven to
be refractory to antiretroviral therapy. He presented to the emergency room with severe
oral pain and odynophagia developing over 2 weeks, limiting his nutritional intake
significantly with 10 pounds of weight loss. Additional medical history was significant
for seizures and a cerebrovascular accident (CVA) 4 years prior. On review of systems,
he denied fevers, diarrhea, or skin lesions; however, he reported several months of
painful tingling in both feet that was worsened when wearing socks and shoes. Medications
on admission included sulfamethoxazole-trimethoprim, valacyclovir, azithromycin, fluconazole,
as well as several antiretroviral agents.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?.AIDS Res Hum Retroviruses. 2008; 24: 1281-1284
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies.Lancet. 2008; 372: 293-299
- Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals.Arch Neurol. 1993; 50: 167-171
- Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy.Mol Pain. 2009; 5: 48
- Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway.AIDS. 1998; 12: 1735-1744
- Age and height predict neuropathy risk in patients with HIV prescribed stavudine.Neurology. 2009; 73: 315-320
- Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.Neurology. 1999; 52: 607-613
- Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex.Neurology. 1988; 38: 794-796
- Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER Study.Arch Neurol. 2010; 67: 552-558
- Subclinical peripheral nerve involvement in AIDS: An electrophysiological and pathological study.J Neurol Neurosurg Psychiatry. 1991; 54: 318-324
- A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.J Neurol. 2004; 251: 1260-1266
- Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: An adult AIDS clinical trials group study.AIDS. 2005; 19: 1341-1349
Joint United Nations Programme on HAU: AIDS epidemic update: December 1999. AIDS Anal 10:2, 2000
- Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.Clin Infect Dis. 2005; 40: 148-157
- Inflammatory neuropathy in homosexual men with lymphadenopathy.Neurology. 1985; 35: 1479-1483
- HIV neuropathy in South Africans: Frequency, characteristics, and risk factors.Muscle Nerve. 2010; 41: 599-606
- Decline in the AIDS and death rates in the EuroSIDA study: An observational study.Lancet. 2003; 362: 22-29
- HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank.Arch Neurol. 2004; 61: 546-551
Moyle G: Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936; discussion 898, 2000
- Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials.PLoS One 5. 2010; : e14433
- Gracile tract degeneration in patients with sensory neuropathy and AIDS.Neurology. 1988; 38: 265-271
- Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.Jama. 1998; 280: 1590-1595
- Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.Neurology. 2008; 70: 2305-2313
- Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial.Neurology. 2010; 74: 413-420
- Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 9: 153-161
- Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.HIV Med. 2007; 8: 367-373
- Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey.Arch Neurol. 1988; 45: 945-948
- Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy.J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 9: 379-388
- HIV-associated neuropathic pain: Epidemiology, pathophysiology and management.CNS Drugs. 2005; 19: 325-334
- Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy.Pain. 2007; 133: 47-63
- An analysis of factors associated with HIV-related peripheral neuropathy.Neurol Infect Epidemiol. 1997; 2: 33-37
- Phase I studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).Lancet. 1988; 1: 76-81
Article info
Publication history
Published online: May 19, 2011
Footnotes
Address reprint requests to Dr J.A. Paice, Northwestern University Medical School, 676 North St Clair Street, Suite 850, Chicago, IL 60611-2927. E-mail: [email protected]
Identification
Copyright
© 2011 American Pain Society. Published by Elsevier Inc. All rights reserved.
